{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:08:53Z","timestamp":1793052533666,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.05.105","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T11:15:50Z","timestamp":1562238950000},"page":"283-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Dermatomyositis: Diagnosis and treatment"],"prefix":"10.1016","volume":"82","author":[{"given":"Reid","family":"Waldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline E.","family":"DeWane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.05.105_bib1","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jaad.2019.05.105_bib2","doi-asserted-by":"crossref","first-page":"1057.e13","DOI":"10.1016\/j.crad.2018.07.106","article-title":"T2 mapping in dermatomyositis\/polymyositis and correlation with clinical parameters","volume":"73","author":"Ran","year":"2018","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jaad.2019.05.105_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.05.105_bib4","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1136\/annrheumdis-2017-212774","article-title":"Performance of the 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice","volume":"77","author":"Ho\u010devar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.05.105_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib6","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jaad.2019.05.105_bib7","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.05.105_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.revmed.2018.11.003","article-title":"Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1\/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017","volume":"40","author":"Victor","year":"2019","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jaad.2019.05.105_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2019.05.105_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.05.105_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2019.05.105_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/BOR.0000000000000535","article-title":"The diagnostic work-up of cancer-associated myositis","volume":"30","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.170544","article-title":"Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118781895","article-title":"The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis\/polymyositis patients: a retrospective study","volume":"6","author":"Lim","year":"2018","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.jaad.2019.05.105_bib16","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s10067-017-3794-3","article-title":"Multiple values of 18F-FDG PET\/CT in idiopathic inflammatory myopathy","volume":"36","author":"Li","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib17","doi-asserted-by":"crossref","first-page":"e9639","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2019.05.105_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNM.0000000000000981","article-title":"18F-FDG PET\/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications","volume":"40","author":"Maliha","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jaad.2019.05.105_bib19","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.05.105_bib20","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2019.05.105_bib21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2019.05.105_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2018.12.040","article-title":"Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease","volume":"397","author":"Li","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jaad.2019.05.105_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-015-0154-4","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?","volume":"15","author":"Ikeda","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaad.2019.05.105_bib24","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2019.05.105_bib25","first-page":"1","article-title":"Serum neopterin as well\u00a0as\u00a0ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to\u00a0therapy in\u00a0patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis","author":"Nishioka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14397595.2018.1553488","article-title":"KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis\/dermatomyositis, but is not a short-term disease-activity biomarker","volume":"29","author":"Hanaoka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib28","doi-asserted-by":"crossref","first-page":"76129","DOI":"10.18632\/oncotarget.19050","article-title":"Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaad.2019.05.105_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5606\/ArchRheumatol.2017.6175","article-title":"serum interleukin-18 level is associated with disease activity and interstitial lung disease in patients with dermatomyositis","volume":"32","author":"Yang","year":"2017","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib30","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.jaad.2019.05.105_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/14397595.2016.1231102","article-title":"Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis","volume":"27","author":"Sato","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2019.05.105_bib33","first-page":"50","article-title":"Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis","volume":"12","author":"Yoshimasu","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamadermatol.2018.5215","article-title":"Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers","volume":"155","author":"Pinard","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.05.105_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bjd.14227","article-title":"Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort","volume":"174","author":"Galimberti","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib40","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of\u00a0high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.05.105_bib41","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/bjd.16230","article-title":"Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?","volume":"179","author":"Piguet","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0190-9622(84)80263-7","article-title":"Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine","volume":"10","author":"Woo","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.14726","article-title":"Treatment of clinically amyopathic dermatomyositis in adults: a systematic review","volume":"179","author":"Callander","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s42358-018-0035-7","article-title":"Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series","volume":"58","author":"Olivo Pallo","year":"2018","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib46","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases","volume":"27","author":"Gelber","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2019.05.105_bib48","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/09546634.2017.1403549","article-title":"Recent developments on treatment strategies and the prognosis of dermatomyositis: a review","volume":"29","author":"Isak","year":"2018","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2019.05.105_bib49","article-title":"Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: a single institution retrospective chart review","author":"Waldman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10067-016-3443-2","article-title":"Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies","volume":"36","author":"Hayashi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.05.105_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","article-title":"Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases","volume":"56","author":"Dinh","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","article-title":"Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies","volume":"58","author":"de Souza","year":"2018","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib54","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib55","article-title":"Treatment with rituximab in juvenile dermatomyositis: effect on calcinosis","author":"Vargas Lebr\u00f3n","year":"2019","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jaad.2019.05.105_bib56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.jaad.2019.05.105_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2019.02.027","article-title":"Tracking changes in nailfold capillaries during dermatomyositis treatment","volume":"81","author":"Argobi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib58","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib59","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/ced.13607","article-title":"Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis","volume":"43","author":"Galimberti","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","article-title":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","volume":"46","author":"Anh-Tu Hoa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.05.105_bib61","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2019.05.105_bib62","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3537","article-title":"Subcutaneous immunoglobulin in refractory juvenile dermatomyositis","volume":"137","author":"de Inocencio","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2019.05.105_bib63","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood\u00a0concentration monitoring improves the prognosis of\u00a0acute\/subacute interstitial pneumonia in dermatomyositis","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0000000000000487","article-title":"Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis","volume":"23","author":"Shimojima","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib65","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.05.105_bib66","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2019.05.105_bib67","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.40418","article-title":"Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling","volume":"70","author":"Deakin","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib68","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000346573","article-title":"Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis","volume":"225","author":"Clottu","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.05.105_bib69","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jamadermatol.2017.5462","article-title":"Bosentan for cutaneous ulcers in anti-MDA5 dermatomyositis","volume":"154","author":"Combalia","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archderm.144.5.585","article-title":"Response of dystrophic calcification to intravenous immunoglobulin","volume":"144","author":"Schanz","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-006629","article-title":"Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin","volume":"2012","author":"Shahani","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2019.05.105_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2010.08.039","article-title":"Calcinosis cutis: part II. Treatment options","volume":"65","author":"Reiter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","article-title":"Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America","volume":"15","author":"Spencer","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaad.2019.05.105_bib75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.05.105_bib76","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in\u00a0the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jaad.2019.05.105_bib77","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.jaad.2019.05.105_bib78","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000000984","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with\u00a0multidisciplinary therapy including tofacitinib in a patient\u00a0with anti-MDA5 antibody-positive dermatomyositis","author":"Kato","year":"2019","journal-title":"J\u00a0Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1016\/j.jaad.2019.05.105_bib80","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.05.105_bib81","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.05.105_bib82","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated Diagnosis Project for Inflammatory Myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2019.05.105_bib83","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib84","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2019.05.105_bib85","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.05.105_bib86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219323084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219323084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:52:10Z","timestamp":1759272730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219323084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219323084"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.105","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatomyositis: Diagnosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(19)33265-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}